Novartis AG

NVS Healthcare Drug Manufacturers General

Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.

Revenue
+4.67%
EPS
−69.1%
Free cash flow
−17.8%
Total debt
+53.9%

Quarter to September 2026, against a year earlier

162.04 2.94 −1.78%
Market cap
$296.4B
P/E
30.9×
Fwd P/E
23.2×
Dividend yield
2.93%
F-score
8/9
Altman Z
4.13
Beneish M
−2.49
Dividend safety
66/100
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
19.15 16.47 14.05 27.97 7.89 25.73 17.93 15.29 24.98 24.99
Piotroski F-Score
8 6 5 6 8 5 7 7 8 5
P/S ratio
4.72 3.80 4.50 4.48 3.59 4.17 4.31 4.18 3.83 3.38
Altman Z-Score
4.13 3.61 3.85 3.35 3.32 2.99 3.33 3.03 3.35 3.23
Altman Z″-Score (non-manufacturers)
3.35 3.20 3.34 3.62 4.13 2.62 3.02 3.63 3.79 3.84
P/FCF ratio
17.34 14.06 15.10 15.79 14.50 18.04 15.90 15.34 18.12 17.42
Beneish M-Score
(2.49) (2.72) (2.87) (2.79) (2.20) (2.71) (2.86) (2.52) (2.68) (2.65)
P/Operating CF
118.08 46.83 82.36 47.33 48.87 51.94 59.29 51.12 56.39 46.58
Dividend Safety Score
66 — — — — — — — — —
P/B ratio
5.74 4.45 4.49 3.27 2.80 3.67 3.78 2.45 2.59 2.23
EV/Sales
5.10 4.11 4.71 4.64 3.61 4.66 4.64 4.53 4.21 3.71
EV/EBITDA
12.62 12.11 16.53 13.53 16.31 17.49 18.20 20.67 20.40 12.69
EV/FCF
18.76 15.21 15.83 16.37 14.57 20.16 17.11 16.63 19.91 19.09
Current Ratio
1.12 1.04 1.16 1.29 1.51 0.90 1.04 1.20 1.21 1.12
Net Debt/EBITDA
0.96 0.78 0.56 0.49 0.07 1.50 1.07 1.19 1.27 1.11
Debt/Equity
0.72 0.67 0.53 0.44 0.43 0.64 0.49 0.41 0.38 0.32
ROE
30.84% 26.28% 27.97% 10.93% 38.59% 14.39% 17.48% 16.49% 10.33% 8.83%
ROA
13.12% 11.81% 13.66% 5.58% 18.51% 6.56% 8.89% 9.05% 5.85% 5.13%
ROIC
16.10% 15.08% 10.72% 7.45% 10.64% 7.82% 7.94% 5.54% 5.78% 5.68%
Return on Tangible Assets
100.14% 114.05% 109.15% 36.57% 88.79% 90.93% 88.15% 58.24% 36.22% 36.55%
Average Days of Receivables
58.88 53.32 58.93 69.99 57.18 61.86 64.15 71.06 64.08 61.71
Earnings Yield
5.22% 6.07% 7.12% 3.58% 12.67% 3.89% 5.58% 6.54% 4.00% 4.00%
Free Cash Flow Yield
5.77% 7.11% 6.62% 6.33% 6.90% 5.54% 6.29% 6.52% 5.52% 5.74%
Free Cash Flow per Share
7.95 6.92 6.69 5.65 5.84 5.07 5.76 5.41 4.52 4.05
Book value per Share
24.01 21.87 22.51 27.25 30.24 24.89 24.25 33.93 31.64 31.55
Free Cash Flow
15,421.00 13,971.00 13,897.00 12,325.00 13,088.00 11,533.00 13,198.00 12,549.00 10,607.00 9,604.00
EV/EBIT
16.40 14.61 22.52 25.40 16.31 22.90 24.85 24.83 24.48 22.17
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026